clinical trial · NCT07412288
First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants
Healthy ParticipantsKT-579Placebo
brief summary
This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.
started
Feb 23, 2026
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Feb 27, 2026
official title
A Phase 1, Randomized, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-579 in Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol